Aislinn Antrim, Managing Editor

A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.

Study results demonstrated consistent benefit across higher and lower-risk patients.

Although the United States has surpassed the milestone of 100 million COVID-19 vaccinations, a study found that reaching 200 million will be significantly more challenging as vaccine hesitancy remains.

Continuous glucose monitors were associated with a decline in levels of HbA1c as well as reduced emergency department visits and hospitalizations for hypoglycemia.

After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.

By encouraging patients to find activities they enjoy and celebrating small improvements, health care professionals can help patients improve mild to moderate hypertension and elevated cholesterol.

The vaccine includes all 13 serotypes in the Prevnar 13 vaccine, as well as conjugates for 7 additional serotypes associated with high case-fatality rates, antibiotic resistance, and meningitis.

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

Common precautions to prevent the spread of COVID-19 also decreased the rates of common respiratory illnesses in 2020 and early 2021.

Prescribers should be aware of new, second-generation antihistamines to manage hay fever and outbreaks of hives, according to a recent study.

Two studies in the 1990s identified gum bleeding as a biomarker for vitamin C levels, although this connection somehow disappeared in dental conversations around gum bleeding.

Margetuximab, trastuzumab deruxtecan, and tucatinib have all been approved in the past 2 years for the treatment of various subsets of patients with breast cancer.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.

Guselkumab also showed promising results in the treatment of psoriatic arthritis, with improved disease activity in joints and across multiple domains through 1 year.

Research has also shown activity with sacituzumab govitecan in subsets of patients with triple-negative breast cancer, such as those with active brain metastases.

This group of antibodies is able to attach to the outer layer of HIV at a patch of glycans—chain-like structures of sugars that are on the surface of cells, including the outer shells of viruses.

This is the first approval for secukinumab in a pediatric population in the United States for severe plaque psoriasis.

Study suggests that 8 out of 10 patients with breast cancer who receive treatment with TARGIT-IORT will not need a long course of post-operative external beam radiotherapy.

A combination of 2 bacteria were able to stay in the colon for an extended amount of time, rather than passing through the system quickly like other probiotics.

The researchers found that the proportion of patients requiring in-patient endoscopic interventions for their alcohol-related gastrointestinal and liver conditions increased.

Rates of death among patients with breast cancer due to any cause were 31% higher in states with Medicaid income eligibility limits no greater than 50% of the federal poverty level.

The once-daily, oral atypical antipsychotic medication has the same established antipsychotic efficacy of olanzapine with less weight gain.

Research could allow the study of long-term HIV infections and the testing of new curative therapies.

Findings showed a 34% decrease in the number of mental health services utilized by children under age 19 and a 22% decline in the number of mental health services utilized by adults aged 19 to 64.

The approval represents the first and only oral sphingosine 1-phosphate receptor modulator indicated for adults with moderately to severely active ulcerative colitis.

The body’s relationship with gut bacteria emerges after birth and in early infancy, during important immunological and physiological development.

This is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting.

Both health care providers and the general public said skin dryness is a major obstacle for consistent hand hygiene practices.